EA202191471A1 - Противовоспалительные полипептиды - Google Patents

Противовоспалительные полипептиды

Info

Publication number
EA202191471A1
EA202191471A1 EA202191471A EA202191471A EA202191471A1 EA 202191471 A1 EA202191471 A1 EA 202191471A1 EA 202191471 A EA202191471 A EA 202191471A EA 202191471 A EA202191471 A EA 202191471A EA 202191471 A1 EA202191471 A1 EA 202191471A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inflammatory polypeptides
inflammatory
polypeptides
compositions
methods
Prior art date
Application number
EA202191471A
Other languages
English (en)
Inventor
Джеффри В. Раветч
Эндрю Пинсетик
Original Assignee
Зе Рокфеллер Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/638,905 external-priority patent/US9845358B2/en
Application filed by Зе Рокфеллер Юниверсити filed Critical Зе Рокфеллер Юниверсити
Publication of EA202191471A1 publication Critical patent/EA202191471A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В настоящем изобретении предложены противовоспалительные агенты, композиции и способы лечения воспалительных нарушений.
EA202191471A 2015-03-04 2016-03-04 Противовоспалительные полипептиды EA202191471A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/638,905 US9845358B2 (en) 2011-12-19 2015-03-04 Anti-inflammatory polypeptides

Publications (1)

Publication Number Publication Date
EA202191471A1 true EA202191471A1 (ru) 2022-01-31

Family

ID=56848864

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791937A EA038554B1 (ru) 2015-03-04 2016-03-04 Противовоспалительные полипептиды
EA202191471A EA202191471A1 (ru) 2015-03-04 2016-03-04 Противовоспалительные полипептиды

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201791937A EA038554B1 (ru) 2015-03-04 2016-03-04 Противовоспалительные полипептиды

Country Status (11)

Country Link
US (1) US10844125B2 (ru)
EP (1) EP3265124A4 (ru)
JP (1) JP2018508522A (ru)
KR (1) KR20230028600A (ru)
CN (1) CN107847586A (ru)
AU (1) AU2016226115B2 (ru)
CA (1) CA2978580A1 (ru)
EA (2) EA038554B1 (ru)
IL (1) IL254284B2 (ru)
SG (1) SG11201707166TA (ru)
WO (1) WO2016141262A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP7122002B2 (ja) * 2017-03-01 2022-08-19 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
CN112924671A (zh) * 2021-01-28 2021-06-08 中国医学科学院北京协和医院 一种用于诊断类风湿关节炎合并肺间质纤维化的生物标志物及其用途
WO2024071010A1 (ja) * 2022-09-26 2024-04-04 国立大学法人京都大学 Ｔ細胞の製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
AU2006204791A1 (en) 2005-01-12 2006-07-20 Xencor, Inc Antibodies and Fc fusion proteins with altered immunogenicity
CA2605781A1 (en) 2005-05-09 2007-04-12 Glycart Biotechnology Ag Antigen binding molecules having modified fc regions and altered binding to fc receptors
JP2009504569A (ja) 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
WO2007055916A2 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
NZ572379A (en) 2006-04-05 2012-06-29 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
NZ597651A (en) 2006-10-26 2012-07-27 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008079466A1 (en) 2006-12-20 2008-07-03 Mmr Information Systems, Inc. Antibodies and methods for making and using them
CN101646775B (zh) 2006-12-28 2016-08-24 森托科尔奥索生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
RU2530168C2 (ru) 2007-05-30 2014-10-10 Поустек Акадэми-Индастри Фаундейшн Слитные белки иммуноглобулинов
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2009132130A2 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
MX2012005006A (es) 2009-10-29 2012-06-19 Janssen Biotech Inc Variantes de glicosilacion de anticuerpos.
ES2693232T3 (es) 2010-11-30 2018-12-10 Chugai Seiyaku Kabushiki Kaisha Agente terapéutico que induce citotoxicidad
WO2012139069A2 (en) 2011-04-07 2012-10-11 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
SG10202001596VA (en) 2011-12-19 2020-04-29 Univ Rockefeller Non-sialylated anti-inflammatory polypeptides

Also Published As

Publication number Publication date
JP2018508522A (ja) 2018-03-29
EP3265124A4 (en) 2018-09-12
CA2978580A1 (en) 2016-09-09
SG11201707166TA (en) 2017-09-28
EA201791937A1 (ru) 2018-07-31
EP3265124A1 (en) 2018-01-10
AU2016226115A1 (en) 2017-10-19
AU2016226115B2 (en) 2021-03-25
EA038554B1 (ru) 2021-09-14
CN107847586A (zh) 2018-03-27
US20180051087A1 (en) 2018-02-22
KR20230028600A (ko) 2023-02-28
WO2016141262A1 (en) 2016-09-09
IL254284A0 (en) 2017-10-31
IL254284B1 (en) 2023-03-01
US10844125B2 (en) 2020-11-24
IL254284B2 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
MD3369425T2 (ro) Compoziții care cuprind tulpini bacteriene
MD3360559T2 (ro) Compoziții conținând tulpini bacteriene
MD3204024T2 (ro) Compoziții care conțin tulpini bacteriene
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
EA201591615A1 (ru) Замещенные ксантины и способы их применения
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы